PharmaCyte Biotech, Inc. (PMCB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

PharmaCyte Biotech, Inc. (PMCB) is up 3.8% since the beginning of the year. At $1 per share, PMCB is trading 50.3% below its 52-week high of $2. Investors who bought $1,000 worth of PMCB shares 5 years ago would now be looking at an investment worth $40.

PharmaCyte Biotech, Inc. (PMCB) has returned 3.76% so far this year and -31.71% over the past 12 months. Over the last ten years, PMCB has returned -38.82% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Sep 17, 2010, PMCB's average daily return is +0.25%, while the average monthly return is +2.78%. At this rate, an investment would double in approximately 2.1 years.

Historically, 39% of months were positive and 61% were negative. The best month was Jan 2021 with a return of +168.7%, while the worst month was Aug 2021 at -71.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 10 months.

On a daily basis, PMCB closed higher 40% of trading days. The best single day was Aug 18, 2021 with a return of +189.5%, while the worst single day was Aug 19, 2021 at -64.9%.

PharmaCyte Biotech, Inc. has an annualized alpha of 79.33%, beta of 0.25, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 20, 2010.

• This stock participated in 142.29% of S&P 500 Index downside but only 17.09% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.25 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PMCB ranks 27 for risk / return — below 27% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for PharmaCyte Biotech, Inc. (PMCB) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the PharmaCyte Biotech, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the PharmaCyte Biotech, Inc. was 99.92%, occurring on Nov 20, 2025. The portfolio has not yet recovered.

The current PharmaCyte Biotech, Inc. drawdown is 99.90%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of PharmaCyte Biotech, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how PharmaCyte Biotech, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.